Aug 19 |
AbbVie, Genmab receive European approval for Tepkinly in follicular lymphoma
|
Aug 19 |
European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
|
Aug 19 |
High Growth Tech Stocks To Watch This August 2024
|
Aug 18 |
AbbVie Inc. (NYSE:ABBV) is largely controlled by institutional shareholders who own 73% of the company
|
Aug 18 |
3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More
|
Aug 18 |
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
|
Aug 17 |
3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income
|
Aug 15 |
These 10 drugs will be cheaper after Medicare negotiations
|
Aug 15 |
AbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process
|
Aug 15 |
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
|